Item 7.01 Regulation FD Disclosure.

On December 16, 2021, the Company made available an Investor Presentation relating to the Transaction described in Item 8.01 of this 8-K. A copy of this Investor Presentation is attached to this Current Report on Form 8-K and furnished as Exhibit 99.1.

The information in this Item 7.01 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall any of it be deemed incorporated by reference in any filing under the Securities Act of 1933, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01. Other Events.

On December 16, 2021, the Company acquired all of the outstanding equity interests in Bio-Flex Solutions, L.L.C. ("BioFlex Solutions") and Newton T & M Corp. ("NTM") for cash consideration, pursuant to an Equity Purchase Agreement, dated as of November 29, 2021, by and among the Company, BioFlex Solutions, NTM, Ralph Meola, an individual, and Jason Nisler, an individual ("Transaction").

Item 9.01. Financial Statements and Exhibits.




(d)   Exhibits

99.1 Investor Presentation furnished by Repligen Corporation.

104 Cover page from this Current Report on Form 8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses